Germany funds psilocybin study with €2.6m

Germany’s Federal Ministry of Education and Research (BMBF) has granted €2.6m to a study investigating the potential effectiveness of psilocybin as an antidepressant treatment for people who cannot tolerate conventional treatments. The “Efficacy and safety of Psilocybin in treatment-resistant major depression” (EpisoDE) study was launched by the Central Institute for Mental Health (CIMH) Mannheim in 2021. The purpose of this study is to determine whether psilocybin is an effective treatment for people with severe depression.

More information

'DMN' or how psychedelics can help with mental disorders

How can psychedelics help with mental disorders? For that we should first ask ourselves what mental disorders consist of. Simplistically, we could say that when there is a disconnect between our higher models of the world and reality, mental disorders such as depression and addictions occur. Our overactive default network (DMN) filters information in an unhealthy way, controlling how we think, behave and see the world. This limits our ability to relate to situations realistically, reinforcing harmful patterns rather than allowing us to change.

More information